Oncology On targeted radiotherapeutics, with Marc Hedrick Dr Marc Hedrick, president and CEO of Plus Therapeutics, discusses developing targeted radiotherapeutics.
News After setback, Rhythm gets good news on Imcivree from FDA Rhythm Pharma has secured the first approval in the US for a drug to treat hypothalamic obesity.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
